Skip to content
DataLookout
Menu

VITALIZENCT06290141

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

StatusRecruiting
PhasePhase 3
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 41 versions: 39 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 133 → 138 locations
  2. Minor Study sites: 133 to 134
  3. Notable Eligibility criteria expanded, about 44 words
    • Study sites: 135 to 133
  4. Minor Trial sites expanded: 129 → 135 locationsv38
  5. Minor Study sites: 128 to 129v36
  6. Minor Trial sites expanded: 123 → 128 locationsv35
  7. Minor Site contacts updated at 1 of 123 sitesv34
  8. Minor Study sites: 122 to 123v33
  9. Minor Trial sites expanded: 118 → 122 locationsv32
  10. Minor Trial sites expanded: 115 → 118 locationsv31
  11. Minor Site details revised at 4 of 115 sitesv30
  12. Minor Study sites: 113 to 115v29
  13. Notable Eligibility criteria shortened, about 355 words
    • Secondary endpoints revised (21)
    v28
  14. Minor Site details revised at 1 of 113 sitesv27
  15. Minor Study sites: 112 to 113v26
  16. Minor Study sites: 111 to 112v25
  17. Minor Study sites: 108 to 111v23
  18. Minor Study sites: 107 to 108v22
  19. Minor Study sites: 105 to 107v21
  20. Minor Study sites: 100 to 105v20
  21. Minor Study sites: 94 to 100v19
  22. Notable Primary completion date: Nov 5, 2025 to Jul 9, 2027
    • Study sites: 92 to 94
    • Study completion date: Nov 19, 2027 to Jan 12, 2029
    v18
  23. Minor Study sites: 90 to 92v17
  24. Minor Study sites: 89 to 90
    • Study completion date: May 19, 2027 to Nov 19, 2027
    v16
  25. Minor Study sites: 85 to 89v15
  26. Minor Study sites: 82 to 85v14
  27. Minor Study sites: 81 to 82v13
  28. Minor Study sites: 78 to 81v12
  29. Minor Study sites: 70 to 78v11
  30. Notable Eligibility criteria expanded, about 18 wordsv10 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 69 to 70
    • Interventions: IVIg (Drug), IVIg premedication (Drug), Placebo (Drug), Placebo (Drug), Placebo (Drug), riliprubart (Drug), riliprubart (Drug) to IVIg (Drug), Placebo (Drug), Placebo (Drug), Placebo (Drug), riliprubart (Drug), riliprubart (Drug)
    • Secondary endpoints revised (21)
  31. Minor Study sites: 62 to 69v9
  32. Minor Study sites: 49 to 62v8
  33. Minor Study sites: 43 to 49v7
  34. Minor Study sites: 28 to 43v6
  35. Minor Study sites: 23 to 28v5
  36. Minor Study sites: 1 to 23
    • Start date changed from estimate of May 31, 2024 to Aug 21, 2024
    v4
  37. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 18, 2024 to May 31, 2024
    • Study sites: 0 to 1
    v3
  38. Minor Start date: Mar 27, 2024 to Apr 18, 2024v2
  39. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of participants experiencing a response
Timeframe: Baseline to week 24
Percentage of participants randomized to riliprubart who responded during part A and had a lasting response during the open-label treatment extension period
Timeframe: Baseline to week 48

Secondary (21)

Change from baseline in Rasch-built Overall Disability Scale (I-RODS) score
Change from baseline in adjusted inflammatory neuropathy cause and treatment (INCAT) disability score
Change from baseline in grip strength (kilopascals, dominant hand)
Change from baseline in Medical Research Council Sum Score (MRC-SS)
Change from baseline in the Rasch-built modified fatigue severity scale (RT-FSS)
Show 16 moreShow less
Percentage of participants experiencing a relapse
Change from baseline in the EuroQol 5 Dimension, 5-Level Health Scale (EQ-5D-5L)
Number of participants with TEAEs, including SAEs and AESIs for Part A
Number of participants with treatment-emergent ADA in participants treated with riliprubart
Number of participants with TEAEs, including SAEs and AESIs
Incidence and titer of anti-drug antibodies (ADA) during open-label treatment and follow-up
Change from baseline in I-RODS
Change from baseline in adjusted INCAT score
Change from baseline in grip strength (kilopascals; dominant hand)
Change from baseline in MRC-SS
Change from baseline in EQ-5D-5L score
Percentage of participants randomized to IVIg continuation who experienced a response
Percentage of participants randomized to riliprubart who experienced a response at Week 48 without prior response in Part A (delayed response)
Percentage of participants randomized to riliprubart experiencing a relapse
Percentage of participants randomized to IVIg continuation experiencing a relapse
Change from baseline in RT-FSS

Arms and interventions

Riliprubart ArmExperimental

Riliprubart + Placebo IVIg for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks

IVIg ArmActive comparator

IVIg (IVIg continuation) + Placebo riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks

Drugs: riliprubart, Placebo, IVIg

Sites

138 sites in 24 countries

United States 32, China 17, Spain 10, Germany 9, Japan 9, Brazil 6, Czechia 5, France 5, Italy 5, Portugal 5, Turkey (Türkiye) 5, Canada 4, Hungary 4, Argentina 3, Taiwan 3, United Kingdom 3, Belgium 2, Denmark 2, Greece 2, Mexico 2, Switzerland 2, Israel 1, Norway 1, Sweden 1